1. Home
  2. Analysis
  3. Zolpidem-tartrate
  4. Hyperlactacidaemia

Zolpidem tartrate and Hyperlactacidaemia - a phase IV clinical study of FDA data

Summary:

Hyperlactacidaemia is reported as a side effect among people who take Zolpidem tartrate (zolpidem tartrate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Amlodipine, and have Suicide attempt.

The phase IV clinical study analyzes which people have Hyperlactacidaemia when taking Zolpidem tartrate. It is created by eHealthMe based on reports of 31,142 people who have side effects when taking Zolpidem tartrate from the FDA, and is updated regularly.

What is Zolpidem tartrate?

Zolpidem tartrate has active ingredients of zolpidem tartrate. It is often used in insomnia. eHealthMe is studying from 32,177 Zolpidem tartrate users. Check the latest studies of Zolpidem tartrate.

What is Hyperlactacidaemia?

Hyperlactacidaemia (the acidosis and also reduces the capacity of the kidney) is found to be associated with 241 drugs and 272 conditions by eHealthMe. Check the latest studies of Hyperlactacidaemia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

31,142 people reported to have side effects when taking Zolpidem tartrate.
Among them, 13 people (0.04%) have Hyperlactacidaemia.

Could Zolpidem tartrate cause Hyperlactacidaemia?

Among these 13 people:

How long have people been on Zolpidem tartrate when they have Hyperlactacidaemia? *

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Hyperlactacidaemia when taking Zolpidem tartrate? *

  • female: 54.55 %
  • male: 45.45 %

What is the age of people who have Hyperlactacidaemia when taking Zolpidem tartrate? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 9.09 %
  • 30-39: 9.09 %
  • 40-49: 18.18 %
  • 50-59: 18.18 %
  • 60+: 45.45 %

What are other drugs people take besides Zolpidem tartrate? *

  1. Amlodipine: 3 people, 23.08%
  2. Valproate Sodium: 2 people, 15.38%
  3. Tranxene: 2 people, 15.38%
  4. Amaryl: 2 people, 15.38%
  5. Amisulpride: 2 people, 15.38%
  6. Atarax: 2 people, 15.38%
  7. Depakote: 2 people, 15.38%
  8. Actos: 2 people, 15.38%
  9. Nexium: 2 people, 15.38%
  10. Hydroxyzine: 1 person, 7.69%

What are other side effects people have besides Hyperlactacidaemia? *

  1. Consciousness - Decreased: 7 people, 53.85%
  2. Metabolic Acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body): 6 people, 46.15%
  3. Hypotension (abnormally low blood pressure): 6 people, 46.15%
  4. Cardiogenic Shock (inadequate circulation of blood): 4 people, 30.77%
  5. Acute Kidney Failure: 4 people, 30.77%
  6. Haemodynamic Instability (disturbances in the blood movement in our body): 4 people, 30.77%
  7. Bezoar (mass found trapped in the gastrointestinal system): 3 people, 23.08%
  8. Hypokalemia (low potassium): 3 people, 23.08%
  9. Heart Rate Decreased: 3 people, 23.08%
  10. Blood Bicarbonate Decreased: 3 people, 23.08%

What are the existing conditions these people have? *

  1. Suicide Attempt: 4 people, 30.77%
  2. Type 2 Diabetes: 2 people, 15.38%
  3. Poisoning Deliberate: 2 people, 15.38%
  4. Pneumonia: 1 person, 7.69%
  5. Inflammation: 1 person, 7.69%
  6. Infection: 1 person, 7.69%
  7. High Blood Pressure: 1 person, 7.69%
  8. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 1 person, 7.69%
  9. Enlarged Prostate: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Zolpidem tartrate and have Hyperlactacidaemia?

- Check whether Hyperlactacidaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zolpidem tartrate:

Hyperlactacidaemia treatments and more:

How severe was Hyperlactacidaemia and when was it recovered:

Expand to all the drugs that have ingredients of zolpidem tartrate:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zolpidem tartrate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperlactacidaemia:

Browse all the conditions that are associated with Hyperlactacidaemia:

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on zolpidem tartrate (the active ingredients of Zolpidem tartrate) and Zolpidem tartrate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.